New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2013
07:13 EDTDCTHDelcath Systems announces reimbursement for Chemostat in Chermany
Delcath Systems announced that the Institut für das Entgeltsystem im Krankenhaus, the German federal reimbursement agency, has established a reimbursement pathway for the treatment of patients with liver metastases with the Delcath Hepatic CHEMOSAT Delivery System for melphalan hydrochloride. The Value 4 status given to the CHEMOSAT procedure, while not mandating reimbursement, allows participating cancer centers to negotiate reimbursement coverage for the CHEMOSAT procedure with all insurers serving their region. Under the NUB scheme, reimbursement pathways will potentially be available for treatment with CHEMOSAT regardless of primary cancer origin.
News For DCTH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 23, 2015
10:07 EDTDCTHDelcath Systems management to meet with Roth Capital
Subscribe for More Information
April 22, 2015
07:11 EDTDCTHCardiovascular & Interventional Radiological Society of Europe holds conference
Subscribe for More Information
April 21, 2015
08:06 EDTDCTHDelcath Systems approves amendments to its CTAs filed in U.K. and Germany
Delcath Systems announces approval of amendments to its Clinical Trial Authorizations, or CTAs, filed with the U.K.'s Medicines and Healthcare Products Regulatory Agency and Germany's Federal Institute for Drugs and Medical Devices for the expansion of the Company's global Phase 2 program for the treatment of patients with unresectable hepatocellular carcinoma, to include a cohort of patients with intrahepatic cholangiocarcinoma.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use